Navigation Links
/C O R R E C T I O N -- Rosetta Genomics Ltd/
Date:5/21/2008

ability to obtain coverage and payment from health plans and payers for diagnostic and therapeutic products applying Rosetta's technology and Rosetta's short operating history; as well as those risks more fully discussed under "Key Information - Risk Factors" in Rosetta's Annual Report on Form 20-F for the year ended December 31, 2006 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

ROSETTA GENOMICS LTD. AND ITS SUBSIDIARY

(A development stage company)

CONSOLIDATED BALANCE SHEETS

U.S. dollars in thousands

March 31, December 31,

2008 2007

Unaudited

ASSETS

CURRENT ASSETS:

Cash and cash equivalents $ 9,511 $ 13,590

Short-term bank deposits 114 112

Marketable securities 8,964 8,251

Other accounts receivable and prepaid

expenses 405 297

Total current assets 18,994 22,250

LONG-TERM INVESTMENTS 2,089 2,391

SEVERANCE PAY FUND 171 144

PROPERTY AND EQUIPMENT, NET 1,340 1,253

Total assets $ 22,594 $ 26,038

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT L
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... The empty capsules market is experiencing growth primarily ... innovations in the empty capsules market. The fast-growing ... of the empty capsules market. , Get Full ... Report , The report will enrich both established ... gauge the pulse of the market which in ...
(Date:12/19/2014)... NEW YORK , Dec. 18, 2014 ... novel therapies for the treatment of chronic pain, announced ... held today. "This was a transformational year ... a promising future for our company," said Sergio ... past year, we have executed on key financial, human ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and ... the Huntsworth Health Group, is proud to announce the ... her role, Gonzales will serve as Senior Vice President ... to welcome a talent of Jamie’s caliber to the ... “She is a proven healthcare innovation leader and brand ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
... Epeius Biotechnologies ( www.epeiusbiotech.com ) announced today that the U.S. ... anti-cancer agent, Rexin-G , the first, and so far ... out and destroy metastatic cancer. According to Dr. Maria Gordon, ... of clinical development, is that the Rexin-G product, with its ...
... ("ShengdaTech" or the "Company") (NASDAQ: SDTH ), ... China, today announced that Mr. Xiangzhi Chen, the Company,s ... CFO and Mr. A. Carl Mudd, lead independent director, ... Conference to be held from March 6-8, 2011 in ...
... 2011 CSL Behring announces a ... released in conjunction with Rare Disease Day 2011 , ... their impact on people,s lives. The Dialogue spanned ... important information and ideas for patients, caregivers and healthcare providers. ...
Cached Biology Technology:Epeius Biotechnologies' REXIN-G, a Tumor-Targeted Genetic Medicine for Metastatic Cancer, Gains Phase 3 Product Designation From the U.S. FDA 2ShengdaTech to Present at Rodman & Renshaw Annual China Investment Conference in Shanghai 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 2Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 3Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 4Thought Leaders in Europe and US Address Challenges to Making Rare Diseases a Global Public Health Priority 5
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... and, new research shows, an infrared laser can make a ... and Vanderbilt University found that pulsed light can pace contractions ... the tissue. The work, "Optical pacing of the embryonic heart," ... Nature Photonics on Aug. 15, 2010. According to ...
... 27 BIO-key International, Inc. (OTC Bulletin Board: http://photos.prnewswire.com/prnh/20050509/BIOKEYLOGO ) ... What: , BIO-key International, Inc. Second Quarter ... Thursday, July 29, 2010 - 10:00 a.m. Eastern Time ... Live via phone by dialing 800-860-2442 and asking for the BIO-key call ...
... 13, 2010The easy accessibility of the eye and the ... offer hope for using gene therapy to provide long-term ... Human Gene Therapy, a peer-reviewed journal published by Mary ... replacement of a human gene to preserve photoreceptor function ...
Cached Biology News:A heart beats to a different drummer 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 2BIO-key® Announces Second Quarter 2010 Earnings Release and Conference Call Schedule 3Promising results of gene therapy to treat diseases of the eye 2
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Biology Products: